Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)

Circulation

Volumn 118, Issue 16, 2008, Pages 1643-1650

  Pitt, Bertram ^a,e   Bakris, George ^b   Ruilope, Luis M ^c   DiCarlo, Lorenzo ^d   Mukherjee, Robin ^d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d PFIZER INC   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Aldosterone; Heart failure; Kidney; Mineralocorticoid receptors; Myocardial infarction; Potassium

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; POTASSIUM; ALDOSTERONE ANTAGONIST; DRUG DERIVATIVE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED DISORDER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; INCIDENCE; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL;

AGED; ALDOSTERONE ANTAGONISTS; FEMALE; HEART FAILURE; HUMANS; HYPERKALEMIA; INCIDENCE; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; POTASSIUM; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 55949112567     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.778811     Document Type: Article

References (20)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, and the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
3. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-1140.
4. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-541.
5. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
6. Shah KB, Krishnamurti R, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845-849.
7. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc Drugs Ther. 2001;15:79-87.
8. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139: 137-147.
9. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
10. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
11. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003;18:1814-1819.
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
13. Anton C, Cox AR, Watson RD, Ferner RE. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther. 2003;28: 285-287.
14. Ko DT, Juurlink DN, Mamdani MM, You JJ, Wang JT, Donovan LR, Tu JV. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail. 2006;12:205-210.
15. Hanna MA, Sumodi V, Fagnilli K. The safe use of aldosterone antagonists in patients with chronic heart failure and associated chronic kidney disease facilitated by a protocol in an outpatient clinic. J Am Coll Cardiol. 2006;47(suppl A):261A. Abstract.
16. Wilcox R, Ambrosioni E, Patni R, Koren A, Mukherjee R, Pitt B. Effect of eplerenone in patients with normal renal function and mild renal insufficiency: results from the EPHESUS Trial. Eur Heart J. 2005; 26:277. Abstract.
17. Delgado-Almeida A, Delgado-Leon C. Changes in plasma ionized calcium and RBC K content in severe hyperkalemia: new electrocardiographic concept. Circulation. 2006;114(suppl II):II-466. Abstract.
18. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008;123:138-146.
19. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-heart). Circulation. 1998;98:1510-1516.
20. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155-161.